Alciona Sasu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alciona Sasu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anca Hermenean
“Aurel Ardelean” Institute of Life Sciences, “Vasile Goldiș” Western University of Arad, 310025 Arad, Romania
3 shared publications - Coralia Cotoraci
Doctoral School, Faculty of Medicine, Vasile Goldis Western University of Arad, 310414 Arad, Romania
3 shared publications - Alina Ciceu
“Aurel Ardelean” Institute of Life Sciences, Vasile Goldis Western University of Arad, 86 Rebreanu, 310414 Arad, Romania
2 shared publications - Eftimie Miutescu
Department of Gastroenterology, Faculty of Medicine, Western University “Vasile Goldiș” of Arad, Revoluţiei Boulevard 94, 310025 Arad, Romania
2 shared publications - Hildegard Herman
“Aurel Ardelean” Institute of Life Sciences, Vasile Goldis Western University of Arad, 86 Revolutiei Av., 310144 Arad, Romania
2 shared publications - Adelina Palcu
Department of Hematology, Faculty of Medicine, Vasile Goldis Western University of Arad, 310414 Arad, Romania
1 shared publication
Latest Publications
- Open Access
- 3 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8571
Cucurbiturils in Oxygen Delivery and Their Potential in Anemia Management
Efficient oxygen transport and accurate anemia diagnostics remain significant medical challenges, as current therapies suffer from stability limitations, immunogenic risks, and inadequate sensitivity. Cucurbiturils (CB[n]), a family of pumpkin-shaped supramolecular macrocycles, present promising solutions due to their rigid architecture, hydrophobic cavities, and strong host–guest binding properties. Functional derivatives such as perhydroxy-cucurbit[5]uril can reversibly bind dioxygen under physiological conditions, highlighting their potential as synthetic hemoglobin substitutes. Additionally, cucurbituril-based probes for Fe3+ and folate enable sensitive and selective detection of iron- and folate-deficiency anemia. Biocompatibility assessments in vitro and in vivo indicate low systemic toxicity and acceptable hemocompatibility for homologues such as CB[6], CB[7], and CB[8], though apoptosis, myotoxicity, or cardiotoxicity may occur at elevated concentrations. These data emphasize the need for thorough toxicological evaluation but also demonstrate that cucurbiturils provide a versatile platform for oxygen transport, diagnostic applications, and drug-delivery strategies in anemia management. While their translation to clinical practice is still at an early stage, the structural tunability, stability, and encouraging safety profile of CB[n] macrocycles offer a strong basis for continued biomedical development.
- 3 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (23) , 8571
Open AccessCucurbiturils in Oxygen Delivery and Their Potential in Anemia Management
Efficient oxygen transport and accurate anemia diagnostics remain significant medical challenges, as current therapies suffer from stability limitations, immunogenic risks, and inadequate sensitivity. Cucurbiturils (CB[n]), a family of pumpkin-shaped supramolecular macrocycles, present promising solutions due to their rigid architecture, hydrophobic cavities, and strong host–guest binding properties. Functional derivatives such as perhydroxy-cucurbit[5]uril can reversibly bind dioxygen under physiological conditions, highlighting their potential as synthetic hemoglobin substitutes. Additionally, cucurbituril-based probes for Fe3+ and folate enable sensitive and selective detection of iron- and folate-deficiency anemia. Biocompatibility assessments in vitro and in vivo indicate low systemic toxicity and acceptable hemocompatibility for homologues such as CB[6], CB[7], and CB[8], though apoptosis, myotoxicity, or cardiotoxicity may occur at elevated concentrations. These data emphasize the need for thorough toxicological evaluation but also demonstrate that cucurbiturils provide a versatile platform for oxygen transport, diagnostic applications, and drug-delivery strategies in anemia management. While their translation to clinical practice is still at an early stage, the structural tunability, stability, and encouraging safety profile of CB[n] macrocycles offer a strong basis for continued biomedical development.
- Open Access
- 20 June 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1771
Phytochemical Profiling and Anti-Fibrotic Activities of the Gemmotherapy Bud Extract of Corylus avellana in a Model of Liver Fibrosis on Diabetic Mice
In this study, we aimed to explore the hepatoprotective effects of the gemmotherapy bud extract of Corylus avellana in a model of liver fibrosis on diabetic mice. An evaluation of total flavonoids and polyphenols contents and LC/MS analyses were performed. Experimental fibrosis was induced with CCl4 (2 mL/kg by i.p. injections twice a week for 7 weeks) in streptozotocin-induced diabetic mice. Our results showed a content of 6–7% flavonoids, while hyperoside and chlorogenic acids were highlighted in the bud extract. Toxic administration of CCl4 increased oxidative stress, mRNA expression of the transforming growth factor-β1 (TGF-β1) and Smad 2/3, and reduced Smad 7 expression. Furthermore, up-regulation of α-smooth muscle actin (α-SMA) revealed an activation of hepatic stellate cells (HSCs), while collagen I (Col I) up-regulation and matrix metalloproteinases (MMPs) unbalance led to an altered extracellular matrix enriched in collagen, confirmed as well by a trichrome stain and electron microscopy analysis. Treatment with gemmotherapy extract significantly restored the liver architecture and the antioxidant balance, and significantly decreased collagen deposits in the liver and improved the liver function. Our results suggest that Corylus avellana gemmotherapy extract may have anti-fibrotic effects and could be useful in the prevention and treatment of liver fibrosis. The hepatoprotective mechanism is based on HSC inhibition, a reduction in oxidative stress and liver damage, a downregulation of the TGF-β1/Smad signaling pathway and a MMPs/TIMP rebalance.
- 20 June 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (6) , 1771
Open AccessPhytochemical Profiling and Anti-Fibrotic Activities of the Gemmotherapy Bud Extract of Corylus avellana in a Model of Liver Fibrosis on Diabetic Mice
In this study, we aimed to explore the hepatoprotective effects of the gemmotherapy bud extract of Corylus avellana in a model of liver fibrosis on diabetic mice. An evaluation of total flavonoids and polyphenols contents and LC/MS analyses were performed. Experimental fibrosis was induced with CCl4 (2 mL/kg by i.p. injections twice a week for 7 weeks) in streptozotocin-induced diabetic mice. Our results showed a content of 6–7% flavonoids, while hyperoside and chlorogenic acids were highlighted in the bud extract. Toxic administration of CCl4 increased oxidative stress, mRNA expression of the transforming growth factor-β1 (TGF-β1) and Smad 2/3, and reduced Smad 7 expression. Furthermore, up-regulation of α-smooth muscle actin (α-SMA) revealed an activation of hepatic stellate cells (HSCs), while collagen I (Col I) up-regulation and matrix metalloproteinases (MMPs) unbalance led to an altered extracellular matrix enriched in collagen, confirmed as well by a trichrome stain and electron microscopy analysis. Treatment with gemmotherapy extract significantly restored the liver architecture and the antioxidant balance, and significantly decreased collagen deposits in the liver and improved the liver function. Our results suggest that Corylus avellana gemmotherapy extract may have anti-fibrotic effects and could be useful in the prevention and treatment of liver fibrosis. The hepatoprotective mechanism is based on HSC inhibition, a reduction in oxidative stress and liver damage, a downregulation of the TGF-β1/Smad signaling pathway and a MMPs/TIMP rebalance.
- Open Access
- 20 May 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (10) , 4710
Immunohistochemical Expression Patterns of Tight Junction Proteins, Pro-Apoptotic and Anti-Apoptotic Factors on Progression of Intestinal Mucositis of Onco-Hematological Patients under Epirubicin-Based Chemotherapy
Chemotherapy and radiation are often accompanied by complications such as intestinal mucositis. The aim of this study was to assess by immunohistochemical assay the consequences of epirubicin-based therapy applied to onco-hematological patients, on the mucosal cells that undergo apoptosis and on the tight junction proteins, immediately before and after a short time of chemotherapy administration. We assessed the protein expression and distribution of the pro-apoptotic Bax, anti-apoptotic Bcl-2 and effector Caspase-3 as key proteins in apoptosis pathways and the changes in immunopositivity of Claudin-1 and ZO-1 tight junction proteins. Results show that the Bcl-2 family is involved in intestinal damage via Caspase-3 dependent apoptosis of epithelial cells. Additionally, the intestinal mucositis activates other injurious pathways through a dramatic drop in Claudin-1 and ZO-1 expressions, contributing for a while to a structural and functional integrity disruption of the intestinal epithelium.
- 20 May 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (10) , 4710
Open AccessImmunohistochemical Expression Patterns of Tight Junction Proteins, Pro-Apoptotic and Anti-Apoptotic Factors on Progression of Intestinal Mucositis of Onco-Hematological Patients under Epirubicin-Based Chemotherapy
Chemotherapy and radiation are often accompanied by complications such as intestinal mucositis. The aim of this study was to assess by immunohistochemical assay the consequences of epirubicin-based therapy applied to onco-hematological patients, on the mucosal cells that undergo apoptosis and on the tight junction proteins, immediately before and after a short time of chemotherapy administration. We assessed the protein expression and distribution of the pro-apoptotic Bax, anti-apoptotic Bcl-2 and effector Caspase-3 as key proteins in apoptosis pathways and the changes in immunopositivity of Claudin-1 and ZO-1 tight junction proteins. Results show that the Bcl-2 family is involved in intestinal damage via Caspase-3 dependent apoptosis of epithelial cells. Additionally, the intestinal mucositis activates other injurious pathways through a dramatic drop in Claudin-1 and ZO-1 expressions, contributing for a while to a structural and functional integrity disruption of the intestinal epithelium.
- Open Access
- 13 May 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (10) , 4451
Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma
Multiple myeloma (MM) is one of the most widespread hematological cancers. It is characterized by a clonal proliferation of malignant plasma cells in the bone marrow and by the overproduction of monoclonal proteins. In recent years, the survival rate of patients with multiple myeloma has increased significantly due to the use of transplanted stem cells and of the new therapeutic agents that have significantly increased the survival rate, but it still cannot be completely cured and therefore the development of new therapeutic products is needed. Moreover, many patients have various side effects and face the development of drug resistance to current therapies. The purpose of this review is to highlight the bioactive active compounds (flavonoids) and herbal extracts which target dysregulated signaling pathway in MM, assessed by in vitro and in vivo experiments or clinical studies, in order to explore their healing potential targeting multiple myeloma. Mechanistically, they demonstrated the ability to promote cell cycle blockage and apoptosis or autophagy in cancer cells, as well as inhibition of proliferation/migration/tumor progression, inhibition of angiogenesis in the tumor vascular network. Current research provides valuable new information about the ability of flavonoids to enhance the apoptotic effects of antineoplastic drugs, thus providing viable therapeutic options based on combining conventional and non-conventional therapies in MM therapeutic protocols.
- 13 May 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (10) , 4451
Open AccessBioactive Compounds from Herbal Medicine Targeting Multiple Myeloma
Multiple myeloma (MM) is one of the most widespread hematological cancers. It is characterized by a clonal proliferation of malignant plasma cells in the bone marrow and by the overproduction of monoclonal proteins. In recent years, the survival rate of patients with multiple myeloma has increased significantly due to the use of transplanted stem cells and of the new therapeutic agents that have significantly increased the survival rate, but it still cannot be completely cured and therefore the development of new therapeutic products is needed. Moreover, many patients have various side effects and face the development of drug resistance to current therapies. The purpose of this review is to highlight the bioactive active compounds (flavonoids) and herbal extracts which target dysregulated signaling pathway in MM, assessed by in vitro and in vivo experiments or clinical studies, in order to explore their healing potential targeting multiple myeloma. Mechanistically, they demonstrated the ability to promote cell cycle blockage and apoptosis or autophagy in cancer cells, as well as inhibition of proliferation/migration/tumor progression, inhibition of angiogenesis in the tumor vascular network. Current research provides valuable new information about the ability of flavonoids to enhance the apoptotic effects of antineoplastic drugs, thus providing viable therapeutic options based on combining conventional and non-conventional therapies in MM therapeutic protocols.